Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.

On Monday, one of the largest acquisitions of 2026 closed, almost one year to the day after it was first announced. This is Kimberly-Clark's (NASDAQ:KMB) purchase of consumer healthcare company Kenvue. The two companies said in their original announcement that Kenvue's enterprise value was a cool $48.7 billion or so.

That's immense, even when considering the huge size of both Kimberly-Clark and Kenvue (formerly a business owned by healthcare giant Johnson & Johnson (NYSE:JNJ)). So it'll result in significant changes to the storied Kimberly-Clark. Let's explore what that means for that company's stockholders, particularly since we're days away from its third-quarter earnings release.

Image source: Getty Images.

A behemoth is born

In the press release on the closing of the acquisition, Kimberly-Clark and Kenvue wrote that it "brings together two iconic American companies to create a combined portfolio of complementary products, including 10 billion-dollar brands, that touch nearly half the global population through every stage of life."

This isn't much of an exaggeration. Millions of homes in this country stock products from one or both companies. The hygiene-focused consumer goods titan Kimberly-Clark is the company behind Kleenex tissue and Huggies diapers, to name only two familiar product lines. Kenvue, meanwhile, purveys everyone's favorite headache remedy (Tylenol), the Johnson's Baby product suite, and Listerine mouthwash.

In other words, at a stroke, Kimberly-Clark will be not only a significantly bulked-up consumer goods giant but also the No. 1 company in the industry focused on health and hygiene products. That makes for quite a daunting economic moat.

The deal is a mix of cash and stock. Kenvue investors were to receive $3.50 per share in cash and almost 0.15 of a share of Kimberly-Clark's equity per each of their Kenvue shares. Kenvue's stock was delisted before market open on Monday.

The ownership structure was estimated at 54% held by existing Kimberly-Clark investors, with Kenvue stockholders owning the remainder.

Staying on the throne?

An enterprise value near $50 billion is huge, even for a Kimberly-Clark-sized business. The company said that much of the funding for the cash portion of the Kenvue purchase was raised through a $4.9 billion senior notes flotation and the sale of a 51% stake in its consumer paper and business-to-business (B2B) hygiene products business to Brazil's Suzano (NYSE:SUZ).

The two companies believe they can achieve annual run rate synergies of $2.1 billion within three years after the acquisition's close. This is probably achievable given the adjacent -- at times overlapping -- nature of their product lineups and geographies.

Beyond its extremely familiar leading brands, Kimberly-Clark is renowned for its impressive streak of dividend raises. It's a Dividend King, meaning it has hiked its payout a minimum of once per year for at least half a century. Its current streak is 54 years, but, understandably, some investors are worried about the dividend's future. The financing commitments are heavy with this deal.

Yet Kimberly-Clark's stated goal for years has been to maintain its Dividend King status. Besides, Kenvue isn't its first swallow of a peer company. What I think the company will do is what it's done in the past following large acquisitions: declare incremental raises for a period of years to conserve capital for buyout-related expenses. I don't think any investor should worry about management losing that hard-earned crown.

One shareholder-pleasing activity that has been jettisoned for now is Kimberly-Clark's share buybacks, which the company once effected regularly. And at a monster scale; in 2024, for example, they totaled $1 billion. These tapered off quickly around the time of the acquisition announcement last year and fell to $0 in 2026. We can expect the same for at least a few years.

A stock for the future

It's important to note that, because the acquisition closed on Monday, Kenvue's recent results won't be included in Kimberly-Clark's third-quarter numbers (although we shouldn't be surprised if the new owner provides them anyway to show what a clever deal it engineered). In addition to digesting the usual figures, growth rates, valuations, etc., investors should pay close attention to any management updates on financing the acquisition, maintaining the dividend raise streak, and -- if the subject comes up -- an eventual restoration of share repurchases.

From what we've seen of the acquisition so far and of both companies’ performance, I’d say it’s a good move, even at that eye-watering price. The pair are more complementary than many big companies tying the knot, and, to repeat, that goes not only for product lineups but also for their geographical footprints. I think the anticipated synergies are achievable, and the Kenvue-infused Kimberly-Clark will be a global powerhouse and a tough competitor. I also think it will maintain its vaunted Dividend King status, which is especially encouraging given its high-yield dividend currently pays out at 4.7%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.